AlloSource Launches UroConnex Fascia for Women's Health Procedures

CENTENNIAL, Colo., Oct. 5, 2026 /CourierPR/ -- AlloSource, a life sciences organization based in Centennial, Colorado, has expanded its portfolio with the launch of UroConnex™ Fascia, a human fascia allograft designed for women's health procedures. This new addition aims to support surgeons in addressing critical conditions such as pelvic organ prolapse, fistula, and urinary incontinence.

UroConnex is available in both freeze-dried and frozen formats, offering a range of sizes to provide structural support in surgical sites. The allograft is intended to streamline urogynecological procedures and reduce patient risk by serving as an alternative to autologous fascia. According to Charles Manuele, AlloSource's Senior Director of Soft Tissue Matrices, the launch marks a commitment to innovation and quality in women's health care.

The allograft is terminally sterilized through irradiation to a sterility assurance level (SAL) of 10-6, minimizing the risk of infection. AlloSource, which has served a global marketplace since 1994, now adds UroConnex to its existing portfolio, which includes AlloMend® Duo Acellular Dermal Matrix and AlloWrap® Amniotic Membrane. These products allow surgeons to support repair and reconstruction in critical women's health conditions.

AlloSource continues to partner with medical professionals and biomedical companies to drive innovation and quality in the use of human tissue allografts for medical advancements. The organization's diverse portfolio of allografts is designed to restore functionality and improve the quality of life for patients.

AlloSource, founded in 1994, has been serving a global marketplace and continues to innovate in the field of tissue allografts. The launch of UroConnex further solidifies AlloSource's position as a leader in women's health care solutions.